Brabant Pharma, a pharmaceutical company focused on advancing Brabafen, its novel, low-dose formulation of fenfluramine for the treatment of Dravet syndrome, announces its sponsorship of the Dravet Syndrome Foundation's First Biennial Family and Professional Conference. The Conference will take place June 26-29, 2014 at Lurie Children's Hospital in Chicago with joint sponsorship by Northwestern University's Feinberg School of Medicine. The conference has been approved for AMA PRA Category 1 Credit.
The Conference will bring together Dravet syndrome families and caregivers with leading clinicians and researchers to discuss new developments in the treatment of the syndrome and associated intractable childhood epilepsies. The event will feature more than a dozen clinical topics, as well as parent-to-parent roundtables and opportunities for families to socialize. Brabant Pharma has established a Scholarship Program to cover conference registration and hotel costs for families in need of financial assistance.
"We are pleased to be a key sponsor of the first Dravet Syndrome Foundation Conference and are gratified to be able to fund a scholarship program that supports families who otherwise could not afford to participate. Dravet syndrome is a devastating condition that affects the entire family in myriad ways, including physically, emotionally and economically," noted Rick Stewart, Chairman and Chief Executive Officer of Brabant Pharma.
"Our commitment to this disease is rooted in Brabafen, our lead product candidate for the treatment for Dravet syndrome. We look forward to presenting an additional three-years of clinical data from an ongoing 19-year observational study at the Conference. With 22 years of published research and robust clinical data in Dravet syndrome patients, the effectiveness of Brabafen has been demonstrated over the long-term. Importantly, Brabafen has a proven ability to greatly reduce seizure frequency or eliminate seizures altogether. We look forward to advancing this very promising treatment for the benefit of these children and their families," concluded Mr. Stewart.
About Dravet Syndrome
Dravet Syndrome (also known as Severe Myoclonic Epilepsy of Infancy) is a rare, severe and therapy-resistant form of epilepsy most often caused by an identifiable gene defect that results in abnormal functioning of a sodium channel in the brain. Children with Dravet's Syndrome experience severe, long-lasting, fever-related seizures in the first year of life. Other seizures typically arise later, including myoclonus (involuntary muscle spasms) and status epilepticus (prolonged seizures), which oftentimes result in severe cognitive and developmental impairment. Episodes of status epilepticus require immediate emergency care and can be fatal. Individuals with Dravet syndrome face a higher incidence of SUDEP (sudden unexplained death in epilepsy) and have associated conditions, which also require proper treatment and management. Children with Dravet syndrome do not outgrow this condition and it affects every aspect of their daily lives.
Unless a cure or better treatments for Dravet syndrome and related epilepsies are found, individuals with these disorders face a diminished quality of life. Current treatment options are limited and the prognosis for these children is poor. The constant care and supervision of an individual with such highly specialized needs is emotionally and financially draining on the family members who care for these individuals. For more information visit www.dravetfoundation.org.
About Brabant Pharma
Brabant Pharma is a privately held company focused on advancing the development of Brabafen, a low-dose formulation of fenfluramine for the treatment of Dravet syndrome. The company was founded in 2013 by bringing together 23 years of research and long-term clinical experience in the treatment of Dravet Syndrome by world-leading experts along with a highly experienced management team to deliver a transformational treatment for Dravet patients. Brabant is working closely with regulatory authorities and clinical experts to accelerate the clinical trial timetable and time to regulatory approval. Brabant has received Orphan Drug designation for Brabafen in both the U.S. and Europe. Brabant has met with representatives of the U.S. Food and Drug Administration and the European Medicines Agency, and expects to commence Phase 3 clinical trials in the U.S. and Europe in the second half of 2014. For more information visit www.brabantpharma.com
Anne Marie Fields
Senior Vice President
SOURCE: Brabant Pharma